Novo Integrated Sciences, Inc.
NVOS

$971.78 K
Marketcap
$0.05
Share price
Country
$0.00
Change (1 day)
$1.60
Year High
$0.03
Year Low

Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary health care related products and services. It operates through two segments, Healthcare Services, and Product Manufacturing and Development. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services. It also engages in the assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across various demographics, including pediatric, adult, and geriatric populations. In addition, the company offers eldercare physiotherapy services, such as long-term care homes, retirement homes, community based home care physiotherapy, community based group exercise classes and fall prevention programs, and community-based outpatient clinics; and elderly occupational therapy services for retirement home and community, and long-term care sectors. Further, it offers medical technology services, such as telemedicine and remote patient monitoring; and develops and distributes personalized health and wellness product solutions. The company operates 16 owned clinics. The company was incorporated in 2000 and is based in Bellevue, Washington. Novo Integrated Sciences, Inc. operates as a subsidiary of ALMC-ASAP Holdings, Inc.

marketcap

P/S ratio for Novo Integrated Sciences, Inc. (NVOS)

P/S ratio as of 2023: 1.13

According to Novo Integrated Sciences, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.13. At the end of 2022 the company had a P/S ratio of 4.13.

P/S ratio history for Novo Integrated Sciences, Inc. from 2004 to 2023

P/S ratio at the end of each year

Year P/S ratio
2023 1.13
2022 4.13
2021 4.85
2020 1.17
2019 1.01
2018 2.33
2017 0.62
2016 0.07
2015 0.01
2014 0.00
2013 0.00
2012 0.00
2011 0.00
2010 0.00
2009 0.00
2008 0.00
2007 0.00
2006 0.00
2005 0.00
2004 0.00